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Abstract
Endometrial cancer is the most common gynecologic cancer in developed 
countries with the cumulative risk rate of 1.71%. Endometrial cancer standard 
treatment is surgery. But adjuvant radiotherapy may be recommended for patients 
in advanced age who have high-grade disease, deep myometrial invasion, LVSI 
positivity, risk factors such as large tumor diameter, lymph node invasion, and 
advanced stage disease. Brachytherapy is applied in two ways, namely intra-cavitary 
or interstitial radiation therapy. Intra-cavitary brachytherapy is the presence of a 
therapeutic radioactive isotope within the body space, for example, vaginal and 
intra-uterine brachytherapy. Radioactive isotopes are directly inserted within the 
tissue in interstitial brachytherapy as in the treatment of cervical or endometrial 
cancers that have reached the lateral walls. The intra-cavitary brachytherapy 
technique is the most commonly used technique in gynecologic oncology. Standard 
treatment cannot be performed in a group of patients due to their medical disorders 
and clinical performances. In these patients, definitive radiotherapy is applied 
for clinical stage 1 patients, neo-adjuvant therapy is applied to patients with local 
advanced stage disease and brachytherapy alone or radiotherapy with addition of 
EBRT is applied as palliative treatment in patients who have complaints such as 
bleeding and pelvic pain.
Keywords: endometrial cancer, vaginal brachytherapy, high dose rate (HDR), 
medically inoperable, vaginal boost
1. Introduction
Endometrial cancer is the most common gynecologic cancer in developed 
countries with the cumulative risk rate of 1.71% [1]. The median age at the time 
of diagnosis is 63 years and about 90% of the patients are above 50 years of age. 
However, 4% of the patients are diagnosed under the age of 40 years [2]. The vast 
majority (80%) of endometrial cancer patients are diagnosed at early stages and 
while the 5-year survival rate is 95%, it significantly decreases in patients with local 
and distant metastases (68 and 17%, respectively) [3]. The standard treatment 
of endometrial cancer is total abdominal hysterectomy and bilateral salpingo-
oophorectomy (TAH + BSO). Lymphadenectomy is performed in suitable patients 
when indicated [4, 5]. Adjuvant radiotherapy may be recommended for patients in 
advanced age who have high-grade disease, deep myometrial invasion, LVSI positiv-
ity, risk factors such as large tumor diameter, lymph node invasion and advanced 
stage disease (Table 1)[6, 7, 9].
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The risk groups had previously been addressed in many studies (PORTEC-1, 
GOG 99 studies) and finally a consensus was reached by the European Society For 
Medical Oncology (ESMO), European Society for Radiotherapy and Oncology 
(ESTRO) and the European Society Of Gynecological Oncology (ESGO) in 2014 
(Table 2)[8].
In the randomized controlled studies of GOG (Gynecological Oncology Group) 
99 and PORTEC-1 (Operative Radiation Therapy in Endometrial Cancer), the 
patients who had intermediate risk factors were divided to two groups and while one 
group received external beam radiotherapy (EBRT), the other group was followed-up 
without treatment. The groups in both studies have been presented in Table 1 [6, 9].
No effect could be demonstrated on the overall survival in either of the 
two studies. However, the recurrence rate decreased to 3–6% from 12 to 15% 
in patients with intermediate risk factors who received EBRT. In the subgroup 
analyses, while the recurrence rate decreased to 5–6% from 18 to 26% in patients 
in the high-intermediate (H-I) risk group, it decreased to 2% from 5 to 6% in 
the low-intermediate risk group. Side effects of radiation therapy were seen at a 
high rate in both studies despite an excellent local control. While the toxic effect 
rate was 26% in the EBRT group in PORTEC 1, it was 4% in the untreated group 
(p < 0.0001) [10]. Hematological, genitor-urinary, gastro-intestinal and skin 
complications were also significantly higher in the GOG 99 study group compared 
Risk group Description
Low Stage I endometrioid, erade 1–2, <50% myometrial invasion, LVSI negative
Intermediate Stage I endometrioid, grade 1–2, ≥50% myometrial invasion, LVSI negative
High-intermediate Stage I endometrioid, grade 3, <50% myometrial invasion, regardless of LVSI status
Stage I endometrioid. 1–2, LVSI unequivocally positive, regardless of depth of 
invasion
High Stage I endometrioid, grade 3, ≥50% myometrial invasion, regardless of LVSI status
Stage II
Stage III endometrioid. no residual disease
Non-endometrioid (serous or clear cell or undifferentiated carcinoma, or 
carcinosarcoma)
Advanced Stage III residual disease and stage IVA
Metastatic Stage IVB
Table 2. 
New risk groups to guide adjuvant therapy use.
PORTEC-1 GOG 99
Age >60 See below
Grad· 3 2–3
Myometrial invasion >50% (outer 1/2) >66.6%·(outer 1/3)
Lvmphvasctilar space invasion N/A Present
High-intermediate risk group At least 2/3 of above any age, all three of above risk factors
age > 50, two of above risk factors
age > 70, one of above risk factors
FIGO, International Federation of Gynecology and Obstetrics; PORTEC, postoperative radiation therapy in 
endometrial cancer; GOG, gynecologic oncology group.
Table 1. 
High-intermediate risk groups in FIGO stage I endometrial cancer as defined by PORTEC-1 and GOG 99.
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to the untreated group [6]. In the long-term quality of life data of the PORTEC-1 
study, urinary and intestinal functions were found to be poorer compared to the 
untreated group [11]. Local radiation therapies have come to the foreground due 
to the high incidence of the toxic effects of pelvic EBRT and their significance has 
gradually increased. Brachytherapy is applied in two ways, namely intra-cavitary 
or interstitial radiation therapy. Intra-cavitary brachytherapy is the presence of a 
therapeutic radioactive isotope within the body space, for example, vaginal and 
intra-uterine brachytherapy. Radioactive isotopes are directly inserted within the 
tissue in interstitial brachytherapy as in the treatment of cervical or endometrial 
cancers that have reached the lateral walls. The intra-cavitary brachytherapy 
technique is the most commonly used technique in gynecologic oncology.
2. Vaginal brachytherapy
2.1 Vaginal brachytherapy (VB) application
2.1.1 Vaginal applicators
Various vaginal applicators are available in gynecologic oncology depending 
on the location of the radiation source and whether it contains a cover or not. The 
Fletcher-Suit-Delclos system is among the most commonly used (Figure 1). Vaginal 
ring applicators are mostly used in HDR. Cylinder vaginal applicators, i.e., Delclos 
dome cylinder are used in patients undergoing hysterectomy (Figure 2).
Figure 1. 
Vaginal ring applicator.
Figure 2. 
Cylinder vaginal applicators (Delclos dome cylinder).
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Single-channel cylinder applicator is among the most commonly used applica-
tors; it minimizes the toxic effects as it is simple and since it covers the whole of the 
vaginal surface [12]. Multi-channel vaginal cylinder applicators are less harmful to 
neighboring tissues through providing asymmetrical dose radiation; however, they 
have a higher effect on the vaginal mucosa [13, 14].
Despite the presence of variable applicators, they have similar efficiency in the 
prevention of vaginal recurrence.
2.1.2 Dose depth
Despite the absence of a standard dose depth, vaginal lymphatics were reported 
to proceed 3 mm beneath the mucosa and treatment covering this depth was 
reported to be sufficient. Normally, a 1 cm depth is targeted. The most common 
monotherapy is a 0.5 cm depth and 7 Gy 3 fraction [12]. The doses effective in the 
vaginal surface when used as vaginal boost treatment have been reported by the 
Radiation Therapy Oncology Group [15].
2.1.3 Vaginal length
There is no consensus on the vaginal length to be treated. It has been reported 
that the proximal vagina can be treated between 1 and 10 cm [16]. The American 
Brachytherapy Society (ABS) has reported that the proximal vagina should be 
treated 3–5 cm or including 1/2–1/3 of the vagina [17]. Due to the possibility of high 
toxic doses causing vaginal stenosis and due to the decreasing frequency of distal 
vaginal recurrence, the treatment modalities that cover the whole vagina are gradu-
ally decreasing [12].
2.1.4 Dose rate
All vaginal brachytherapy applications had been carried out as LDR before the intro-
duction of HDR [4]. Historically, low dose hourly 60 cGy had been used widespread in 
most brachytherapy regimens. This treatment modality given as LDR was taking long 
and it required hospitalization. About 96% of brachy therapists have switched to this 
method through the introduction of HDR applicators [17]. The advantages of HDR 
include less radiation exposure of the health staff and visitors as it enables remote con-
trol, thrombo-embolic events are less frequently encountered as the patients are treated 
in the outpatient setting and long-term immobilization is avoided. There is no differ-
ence between LDR and HDR with regard to recurrence and the overall survival [18].
2.1.5 Treatment plan
There are many ways for an accurate treatment plan in VB applications. When 2D 
and 3D CT-based treatment plans were compared, the 3D method was found to be supe-
rior as it reached the clinical target volume and produced less harm to neighboring tis-
sues [19]. Many brachy therapists use the 3D treatment plan and its application at every 
session separately was not found to be superior to single session application, except for 
being expensive [20]. The CT-based treatment plan reveals the air between the vaginal 
cuff and the applicator effectively and enables a more effective treatment [21].
2.1.6 Dose and duration of vaginal brachytherapy
The toxic dose that emerges during VB is related to the amount of the total dose, 
dose velocity, total vaginal length, dose depth and the fraction time. In a study, the 
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patients who received VB with HDR were allocated to four groups as 4 fractions of 
9.0 Gy, 5 fractions of 6.0 Gy, 6 fractions of 5.0 Gy and 6 fractions of 4.5 Gy. A 1 cm 
depth from the vaginal surface was utilized. Vaginal, urinary bladder and rectal tox-
icity were found to increase as the amount of the dose increased along with the frac-
tion [22]. In another study, no grade 2 or above vaginal, urinary bladder and rectal 
toxicity were encountered when 6 fractions of 4.0 Gy VB was applied targeted only 
to the vaginal surface [23]. The ABS recommends HDR VB as 24 treatment schemes 
as monotherapy and the 22 treatment scheme as boost dose [12]. In the PORTEC-4 
study conducted for standardization of the dose and the fraction amount, the 
patients with H-I risk, early stage endometrial cancer were divided into treatment 
and observation groups; the treatment group was randomized as 3 fractions of 7.0 Gy 
or 3 fractions of 5.0 Gy. However, the study was terminated early as the patient 
collection and the untreated group were not proper. Therefore, further studies are 
required for standardization of the dose amount and the duration of fraction.
2.1.7 Protection from vaginal toxicity
Vaginal toxicity is a significant complication of VB and it impairs the quality of 
sexual life due to vaginal atrophy, shortness and narrowness. The sexual activity 
frequency and satisfaction are reduced in patients undergoing surgery and VB [24]. 
In a study, having sexual intercourse during the VB treatment was reported to pre-
vent vaginal shortness and narrowness; however, atrophy-related dyspareunia was 
reported in 2/3 of the patients and furthermore, it was emphasized that the distal 
2/3 of the vagina was more susceptible to toxic effects rather than the proximal 
1/3 of the vagina [22]. Use of vaginal dilator for 6 months following radiotherapy 
was shown to decrease the vaginal stenosis [25]. In the Cochrane database, use of 
vaginal dilator during radiotherapy was not shown to have sufficient evidence. 
However, it accepts the observational studies suggesting that use of the regular 
vaginal dilator may improve the vaginal stenosis rates reported by the patients [26]. 
Estrogen cream is another option for protection of the vagina. Despite the absence 
of sufficient and strong evidence about the use of estrogen creams, they were 
shown to prevent vaginal atrophy in small studies [27]. A selection should be made 
after discussing the benefits and harms of this treatment option with the patient.
3. Adjuvant vaginal brachytherapy treatment
3.1 Adjuvant vaginal brachytherapy as monotherapy
As reported above, we know that pelvic EBRT reduces the recurrence; however, 
it leads to severe side effects compared to follow-up without treatment in endome-
trial cancer. Radiotherapy via the vaginal route was considered to be more proper 
as vaginal recurrences are seen most in post-operative endometrial cancer patients. 
Similarly, with pelvic EBRT, VB treatment was not shown to be effective on the 
overall survival. However, while the vaginal recurrence rate is 0–3.1% in VB, the 
pelvic recurrence rate is 0–4.1% [28–30]. These rates are similar with pelvic EBRT 
and related to the lower toxic effects.
In the randomized controlled PROTEC-2 study comparing the effectiveness 
of pelvic EBRT and VB treatment, all patients were H-I risk endometrial cancer 
patients who had undergone TAH + BSO, but not lymphadenectomy. The patients 
were allocated to three groups as the group that received 23 fractions 46 Gy as pelvic 
EBRT, the high dose rate (HDR) group that received 7 Gyx3 fractions and the low 
dose rate (LDR) group that received 30 Gy VB. While the 5-year vaginal recurrence 
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was 1.8% with VB, it was 1.6% in the pelvic EBRT group (p = 0.74). The pelvic 
recurrence rate was higher in the VB group (3.8% vs. 0.5%, p = 0.02). However, the 
gastrointestinal side effects were significantly lower in the VB group compared to 
the EBRT group [30].
3.2 Adjuvant vaginal brachytherapy as boost
A better loco-regional control can be achieved by adding VB to pelvic EBRT 
and the rate of vaginal recurrence would be seen as 0–2.7% and the rate of pelvic 
recurrence as 0.3–4.0% [29, 31–33]. Despite the absence of EBRT+/-VB random-
ized controlled study, boost VB may be added in the treatment of high risk patients 
whose vaginal recurrence is high and who receive low dose EBRT (45 Gy at 1.8 Gy/
fractions). There are randomized controlled studies comparing EBRT + boost VB 
and VB alone. In one of these studies, while the total pelvic recurrence rate was 
0.4% in EBRT + boost VB group, it was 5.3% in the VB only group (p = 0.013). No 
difference was found between the groups with regard to vaginal recurrence and 
overall survival; however, the radiation toxicity was lower in the VB group [33]. In 
the studies of RTOG, applying 5–6 Gy VB boost only onto the vaginal surface as 
45 Gy EBRTx3 fractions or 50.4 Gy EBRTx2 fractions is recommended [34, 35].
3.3 Vaginal brachytherapy and chemotherapy
The effect of adding chemotherapy (CT) to VB was investigated particularly in 
high risk endometrial cancer patients who had the likelihood of distant metastasis. 
In a study conducted by Landrum et al., the 2-year progression-free survival was 
91% in 23 patients including H-I risk early stage endometrial cancer, uterine serous 
carcinoma (USC) and clear cell carcinoma (CCC). Vaginal recurrence occurred 
in one patient (4.2%); this patient also had distant metastasis [36]. The effect of 
VB + CT was investigated in the GOG 249 randomized controlled study. In that 
study, while one group received EBRT, another group received VB + CT (3 cycles 
of carboplatin and paclitaxel). The study included the GOG 99 H-I risk patients, 
patients with stromal invasion and stage 1–2 USC and CCC. While the overall 
survival was 92% in the EBRT group, it was 92% in the VB + CT group at the end 
of the 2-year follow-up (p = NS). There was no significant difference between the 
vaginal recurrence rates in the two groups. While hematologic toxicity, neuropathy 
and fatigue were more common in the VB + CT arm, grade 2 diarrhea was more 
common in the EBRT arm [37].
4. Vaginal brachytherapy treatment in high-risk histology
More aggressive treatments are used in uterine serous cancer (USC), clear cell 
carcinoma (CCC) and carcino-sarcoma (CS), which are the high risk histologies of 
endometrial cancer [38]. Most of the large studies including PORTEC-1, GOG 99 
and PORTEC-2 [6, 9, 30] included early stage endometrial cancer patients and not 
high-risk patients. However, in the GOG 249 study, 20% of the patients were USC 
and CCC patients [37]. In a study conducted by Creasman et al., the outcomes of 
stage 1 high risk patients were found to be similar to those of grade 3 endometrioid 
type adeno-carcinoma patients [39]. Despite the presence of vaginal recurrence at 
a rate of 0–2.7% in stage 1–2 patients with high risk histology, the pelvic recurrence 
rate was found to be 0–9% [40–43]. In a study investigating USC patients, while 
the 5-year survival rate was 94% in patients who received VB + CT, it was 65% in 
patients who received LDR + EBRT but not CT [40]. In another study, USC patients 
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received VB + CT (six cycles of carboplatin and paclitaxel) and the vaginal, pelvic 
and distant metastasis rates were found to be 0, 9, and 10%, respectively, and the 
5-year survival rate was 90% [41]. The effectiveness of VB alone was investigated 
in endometrial cancer patients with high risk histology. Some authors reported that 
CT did not have a great contribution [42, 43].
4.1 Brachytherapy for treatment of medically inoperable endometrial cancer
As mentioned above, the standard treatment of endometrial cancer is 
TAH + BSO (total abdominal hysterectomy + bilateral salphingo-oopherectomy) 
and lymphadenectomy when indicated, however, this standard treatment cannot 
be performed in a group of patients due to their medical disorders and clinical 
performances. In these patients, definitive radiotherapy is applied for clinical stage 
1 patients, neo-adjuvant therapy is applied to patients with local advanced stage 
disease and brachytherapy alone or radiotherapy with addition of EBRT is applied 
as palliative treatment in patients who have complaints such as bleeding and pelvic 
pain. While LDR VB+/−EBRT has been used recently in the treatment of these 
patients, HDR VB+/−EBRT is widely used today [44, 45]. The treatment of medi-
cally inoperable endometrial cancer patients is planned better and more effectively 
through advancements in radiology.
4.1.1 Patient characteristics
Medically inoperable endometrial cancer patients should be meticulously evalu-
ated pre-operatively by a gynecologic oncologist. Most of these patients have cardiac 
diseases, pulmonary diseases, hypertension, diabetes mellitus, cerebro-vascular 
disease, renal disease, syndromes such as Marfan syndrome, advanced age and 
other malignancies. Morbid obesity is a relative contra-indication for the operation 
depending on the experience of the surgeon and the condition of the patient. Clinical 
performance of the patients is of vital importance as a pre-operative parameter. All 
of these patients should be evaluated pre-operatively for local or general anesthesia 
by experienced anesthetists. The hormone therapy (progestin, aromatase inhibitors) 
option is also available besides the radiotherapy option for clinical stage 1, grade 1 
patients who are not eligible for surgery, for patients with endometrioid type endo-
metrial cancer, for those below the age of 40 years and those willing to have a child 
[46]. Regression has been detected in 55% of the patients treated in this way [47].
Levonorgestrel-releasing intra-uterine devices (LNGIUDs) may be added to 
treatment of patients who have precancerous and stage 1, grade 1 endometrioid 
type endometrial cancer [48]. The patients are meticulously evaluated with CT or 
MRI with regard to tumor diameter, myometrial invasion depth, cervical involve-
ment, ovarian involvement and pelvic para-aortic lymph node involvement if 
hormone therapy is planned, as oral regimens have the likelihood of recurrence 
at a rate of 25% despite the 50% or above success rates [49]. While endometrial 
cancer staging is done surgically according to the recent International Federation of 
Gynecology and Obstetrics (FIGO) 2009 classification, clinical staging is used in 
medically inoperable patients (Table 3) [50].
The patients should be meticulously evaluated for pelvic examination and dis-
tant metastasis if clinical staging would be used. Vagina, cervix and the uterus are 
evaluated, presence of a mass lesion is examined and the search for parametrium 
involvement is attempted through bimanual (rectal-vaginal) examination. Computed 
tomographies of the thorax, abdomen and the pelvis are performed for distant 
metastasis and MRI is used for assessment of the uterus and the pelvis as the negative 
predictive value is >85% for myometrial invasion in contrast-enhanced T2-weighted 
Translational Research in Cancer
8
MRI and the positive predictive value is low [51]. 18-F-fluoro-deoxyglucose positron 
emission tomography (PET) is used for lymph node involvement [52, 53]. In a study 
conducted with PET-CT, the pelvic node involvement rate was 63% and the para-aortic 
lymph node involvement was 95% [54].
4.1.2 Dose standards and technical properties
The target volume has been defined as the whole uterus, cervix and the upper 
3–5 cm of the vagina for inoperable endometrial cancer in the 2000 ABS guideline 
and mainly MRI, and if MRI is not available, CT was recommended for the treat-
ment plan [55]. The risks for the neighboring organs should be considered when 
performing volume-based treatment through MRI or CT [56] (Table 4).
In a study of Gill et al., 38 inoperable endometrial cancer patients underwent 
volume-based treatment and the gross tumor volume (GTV) and the clinical 
target volume (CTV) were determined with MRI in 19 patients and with CT in 
the remaining 19. While 20 patients received a mean 37.5 Gy VB in 4–5 fractions, 
20 patients received 45 Gy EBRT followed by 25 Gy boost VB treatment. While 
the local control rate was 90.6% for 2 years, the overall survival rate was 94.4%. 
Hemorrhage developed in only one patient during the applicator placement and she 
received blood transfusion. No patients had grade 3 or acute and late complications 
[57]. The patients should be referred to centers where MRI or CT is available or their 
treatment should be attempted by using ultrasonography and radiography.
4.1.3 Treatment
1. HDR VB may be used alone in patients who have clinical stage 1, grade 1–2 
myometrial invasion of less than 50 [56]%. GTV is specified in the course 
of brachytherapy with MRI and the whole uterus and its serosa are irradi-
ated (CTV). For minimal harm to the neighboring tissues (OAT), the limit is 
70–75 Gy for the rectum and the sigmoid, and 80–100 Gy for the urinary blad-
der. The HDR dose schemas for these patients have been presented in Table 5.
Structure Image data set Definition
Gross tumor volume 
clinical target volume
Organs at risk
T2-wcightcd MRI 
MRI or CT
MRI or CT
Visible abnormality if present Entire uterus, cervix, 
and upper 1–2 cm of the vagina
Sigmoid, rectum, bladder, bowel, and uninvolved 
lower third of the vagina
CT, computed tomography; MRI, magnetic resonance imaging.
Note. MRI is required if a gross tumor volume is to be contoured. The clinical target volume includes the entire uterus, 
cervix, and upper vagina. Organs at risk include bladder, rectum, and sigmoid.
Table 4. 
Recommended structures for volume-based planning in medically inoperable endometrial cancer.
IA-Uterine cavity sounds to <8 cm
IB-Uterine cavity sounds to >8 cm
Stage II-Involves the corpus and cervix
Stage III-Parametrium, adnexa, or vagina but confined to true pelvis
Stage IVA-Involving local structures (rectum/bladder)
Stage IVB-Metastatic
Table 3. 
Clinical staging system for endometrial cancer.
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2. Pelvic EBRT+HDR VB is recommended for clinical stage 1 patients with myo-
metrial invasion >50%. EBRT is applied 45–50 Gy so as to include all pelvic 
lymph nodes, the whole uterus and 1–2 cm proximal of vagina. Dose schemas 
are presented in Table 6 for these patients.
3. Patients with clinical stage 2 endometrial cancer are given pelvic EBRT + HDR 
VB. This treatment modality is also valid for clinics that do not have MRI. The 
doses presented in Table 6 are used.
4. Higher doses of pelvic EBRT (including all lymphatic regions) up to 
65 Gy + HDR VB are given to patients with clinical stage 3 endometrial cancer. 
The doses presented in Table 6 are used.
4.1.4 Management of recurrent disease after definitive radiation
Radiotherapy options are quite limited in biopsy-proven recurrences after 
definitive radiation treatment. It may only be used for palliative purposes in vaginal 
hemorrhage and pelvic pain. Hormone therapy and chemotherapy options should 
be considered in patients with recurrence [58].
4.2  Treatment-related toxicity from the use of radiation therapy for 
endometrial cancer
In the literature, radiotherapy was shown to have been used in 60% of cervi-
cal cancers, 45% of endometrial cancers and 100% of vaginal cancers [59, 60]. 
Healthy cervical and uterine tissues are known to tolerate radiation therapy (RT) 
well. Although pregnancy is known to have occurred in women receiving 20–30 Gy 
RT for the uterus, an atrophic uterus improper for pregnancy develops in women 
HDR total dose (Gy) HDR dose fractionation EQD2 (Gy)
36 6 Gy × 6 48
38.4 6.4 Gy × 6 52.5
363 7.3 Gy × 5 52.6
34 8.5 Gy × 4 52.4
40–50 5 Gy × 9–10 50–62.5
Table 5. 
HDR dose table.
EBRT (Gy) HDR total dose (Gy) HDR dose fractionation EQD2 (Gy)
45 19.5 6.5 Gy × 3 71.1
45 18.9 6.3 Gy × 3 69.9
45 20.8 5.2 Gy × 4 70.6
45 25 5 Gy × 5 75
45 17 8.5 Gy × 2 70.5
50.4 12 6.0 Gy × 2 65.6
50.4 22.5 3.75 Gy × 6 75.3
Table 6. 
EBRT and HDR dose schemas.
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receiving 40–50 Gy. The toxic effect of RT depends on the age for ovaries; exposure 
to 20 Gy usually results in ovarian insufficiency in an adult woman. The influence 
of RT on the vagina depends on the location (superior, medial, inferior, posterior 
or the anterior wall). While the proximal vagina seems to be resistant to high doses 
(>100 Gy), the distal and the posterior walls are susceptible to atrophy and ste-
nosis. While the rectum and the urinary bladder can be treated with low risk with 
45–50 Gy RT, the small intestine shows severe toxic effects against <30 Gy, depend-
ing on the treated volume. These toxic effects of RT are known to be related to the 
treated tissue amount, fraction number and dose, previous surgeries, concurrent 
chemotherapies, co-morbid conditions and the smoking status [61].
Acute toxicity is defined as conditions that develop in the course of RT.
Sub-acute toxicity is defined as conditions that develop between 4 and 12 weeks 
after termination of RT.
Late toxicity is defined as the irreversible reactions that develop 3 months after 
termination of the treatment.
4.2.1 Genito-urinary (GU) system toxicity
The patient is asked to come to the treatment with a full urinary bladder with 
the aim of moving away the bowels as the urinary bladder can tolerate RT relatively 
better than the bowels.
4.2.1.1 Acute radiation cystitis
This is among the most common RT-induced complications. The patients pres-
ent with urinary symptoms (dysuria, frequency, urgency and nocturia). Infectious 
cystitis should be excluded. The symptoms usually recover spontaneously within 
1–2 weeks. Genitor-urinary complaints were reported to be seen less frequently 
when adjuvant therapy was performed with intensity-modulated radiation therapy 
(IMRT) [62].
4.2.1.2 Late genito-urinary toxicity
This toxic effect of RT emerges as the urinary bladder epithelium and the 
micro-vascular circulation are affected. Fibrosis and collagen accumulate under the 
epithelium and the muscle layer, and the urinary bladder capacity decreases. This 
effect leads to over-activity and contraction of the urinary bladder resulting in urge 
incontinence. In the PORTEC-1 study, while grade 3–4 toxicity was not observed, 
the rate of grade 1–2 genito-urinary complication was 5% higher [11].
Hematuria and ulcer formation are the late GU findings. Recurrent urinary blad-
der stones may be formed. Ureto-vaginal or vesico-vaginal fistulae may also develop 
following brachytherapy [63].
4.2.2 Gastro-intestinal (GI) toxicity
Gastro-intestinal toxicity may develop during RT or later and impair the quality 
of life of the patients through leading to restrictions in the daily lives of the patients.
4.2.2.1 Acute RT toxicity
As the small intestine epithelium shows a rapid proliferation, it is affected to a 
higher extent by RT. While nausea and vomiting are seen at the beginning of the 
11
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treatment, abdominal cramps and diarrhea are experienced during the following 
2–3 weeks. This effect is considered to result from the disappearance of small intes-
tine crypts and the inability to restore them in a short while [64]. The acute effects 
in the colon include fecal urgency and tenesmus. Acute colonic problems are seen 
in approximately 50% of the patients who receive 45–50 Gy as adjuvant; however, 
acute grade 3 toxicity is lower than 3% [10, 30]. There are randomized studies 
reporting that these acute effects may be significantly reduced by using IMRT [65].
4.2.2.2 Late GI toxicity
Late effects may develop between 6 months and several years in most patients. 
The pathophysiology includes chronic enteropathy with mucosal atrophy and loss 
of mucin-producing goblet cells. Fibrosis in the intestinal walls causes dysmotility 
and acute obstruction. There are no techniques that do not cause late intestinal 
complications, including IMRT. The late toxic intestinal effects include chronic 
diarrhea, malabsorption, recurrent ileus, mucosal ulcer, telangiectasias and rectal 
proctopathy.
4.2.3 Vaginal toxicity
Vaginal complications are commonly seen both during pelvic EBRT and VB. This 
toxic effect impairs the quality of life of the patients by leading to sexual dysfunc-
tion. Vaginal toxicity above grade 2 was not reported when the vaginal cuff was 
treated with HDR VB alone in a study [23].
4.2.3.1 Acute vaginal mucositis
Erythema and superficial ulcers develop as a result of vaginal surface epithelium 
injury in patients receiving brachytherapy. This leads to exudative vaginal discharge 
and may result in secondary infections.
4.2.3.2 Vaginal ulceration and necrosis
This complication is particularly seen when interstitial brachytherapy is used for 
treatment of full-thickness vaginal mucosa involvement [66].
4.2.3.3 Vaginal stenosis
This is a common late complication of both pelvic EBRT and VB. Dyspareunia 
is common due to reduced vaginal length. Vaginal stenosis and complete closure 
should be prevented to achieve a satisfactory follow-up. Stenosis usually develops 
3–6 months after therapy. Vaginal dilators with proper thickness and length are 
used for the primary repair in these patients. While some authors propose that the 
use of vaginal dilators after RT reduces the stenosis, some others propose that it is 
not much effective [67].
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